Eli Lilly's Jaypirca Gets Approval in Canada for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
MT Newswires Live
6 hours ago
Eli Lilly's (LLY) Jaypirca is now approved and available in Canada for adult patients with relapsed or refractory mantle cell lymphoma and chronic lymphocytic leukemia, Eli Lilly Canada announced Tuesday.
The drug has received the notice of compliance with conditions by Health Canada based on the response rate from the phase 1/2 study, called the BRUIN trial, the company said.
The pirtobrutinib tablet is approved as an oral prescription medicine in 100 mg or 50 mg taken as a once-daily 200 mg dose.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.